COVID-19疫苗试验中抗体反应检测方法的比较:英国多中心随机对照试验结果,旨在确定COVID-19疫苗与季节性流感疫苗同时接种的免疫原性反应(ComFluCOV)
ComFluCOV试验比较了COVID-19疫苗与流感疫苗同时接种的安全性和免疫原性,使用三种方法检测SARS-CoV2抗刺突抗体反应。所有疫苗组合的几何平均比均超过0.67的非劣效阈值,三种方法间呈中度秩相关,证实同时接种未显著影响免疫原性。
要点
- 所有COVID-19与流感疫苗组合的几何平均比均超过0.67非劣效阈值。
- 三种检测方法间呈中度秩相关。
- 同时接种未显著影响所测试疫苗的免疫原性。
核心结论
- 所有三种检测方法均证实疫苗同时接种未显著影响所测试任何疫苗的免疫原性。
研究设计与样本
- ComFluCOV试验为英国多中心随机对照试验,18岁以上成人接种COVID-19疫苗并同时接种流感疫苗或生理盐水安慰剂。
- 接种后一个月采集血清,使用三种方法检测SARS-CoV2抗刺突抗体。
主要发现
- 所有COVID-19与流感疫苗组合的几何平均比均超过0.67。
- 三种检测方法间呈中度秩相关。
关键数值与推荐
- 几何平均比以0.67为阈值视为非劣效。
- 检测方法包括商业内部酶联免疫吸附试验(ELISA)、商业快速电化学发光免疫分析(ECLIA)和病毒中和试验(VNA)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ComFluCOV trial tested the safety and immunogenicity of COVID-19 and influenza vaccines co-administration. Binding and functional SARS-CoV2 anti-spike responses were measured using assays developed in response to the COVID-19 pandemic. The three assays used to measure the immunogenicity outcomes are reported here and their performance compared to inform future vaccine development. METHODS: Adults aged over 18 were vaccinated with a COVID-19 and either an influenza vaccine or saline placebo. Serum sampled one month after vaccination was used to measure SARS-CoV2 anti-spike antibody concentrations using a commercial in-house enzyme-linked immunosorbent assay (ELISA), a commercial fast throughput electrochemiluminescence immunoassay (ECLIA) and a viral neutralisation assay (VNA). Geometric mean ratios were used to compare the response to COVID-19 with or without influenza vaccine with a threshold of 0.67 considered non-inferior. The relationship between the different assays was examined using Kendall rank correlations. RESULTS: The geometric mean ratios exceeded 0.67 using all assays for all COVID-19 and influenza vaccine combinations tested. Moderate rank correlations were found between the three assays. CONCLUSION: All three assays confirmed that vaccine co-administration did not significantly impact on immunogenicity of any of the vaccines tested. TRIAL REGISTRATION: ISRCTN14391248, registered on 17/03/2021.
引用
- Lazarus R, Harris R, Thirard R, et al. Comparison of assays used to detect antibody response in COVID-19 vaccine trials: Results from of a UK multi-Centre randomised controlled trial to determine the immunogenicity responses of COVID-19 vaccines administered concomitantly with seasonal influenza vaccines (ComFluCOV). Vaccine. 2024. PMID: 39316941. doi:10.1016/j.vaccine.2024.126369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。